Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma

An, Hyo Jung; Ko, Gyung Hyuck; Lee, Jeong-Hee; Lee, Jong Sil; Kim, Dong Chul; Yang, Jung Wook; Kim, Min Hye; Kim, Jin Pyeong; Jung, Eun Jung; Song, Dae Hyun

doi:10.4132/jptm.2017.07.26

Cited by 17 publications

(22 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, our histologic findings revealed both strong membranous and cytoplasmic PD‐L1 expression in patients with advanced‐stage cancer, suggesting its role as a potential marker of thyroid cancer prognosis and aggressiveness . However, it is important to point out that our series included fewer cases of high diagnostic stage ( P = .4842; chi‐square, 2.451 with 3 degrees of freedom).…”

Section: Discussionmentioning

confidence: 72%

“…In our current series, ICC was carried out using the Dako 22C3 clone, which mostly resulted in cytoplasmic PD‐L1 expression and weak or strong, membranous PD‐L1 localization. Although the detection of cytoplasmic PD‐L1 staining is unusual and has been considered nonspecific in lung cancer, it was a common finding in different thyroid lesions in our LBC series …”

Section: Discussionmentioning

confidence: 81%

“…As reported in previous histologic series, we compared PD‐L1 (cytologic and histologic) expression with matched thyroid staging according to the eighth edition of the AJCC Cancer Staging Manual in the 113 malignant cases of our series. The data showed that the majority of patients (n = 105; 93%) had stage I disease, 6 had stage II disease (5.3%), 1 had stage III disease, and 1 other had stage IV disease (Table ).…”

Section: Resultsmentioning

confidence: 99%

“…Increasing PD‐L1 expression in tumor cells has been reported in higher stages and appears to be linked to a high risk of aggressive disease, distant metastases, or death . Chowdhuri et al reported that increasing PD‐L1 expression in thyroid cancer cells correlated with invasiveness of PTC and a poor prognosis, especially in patients with stage III and IVA disease .…”

Section: Discussionmentioning

confidence: 99%

“…For thyroid pathology, the expression of PD‐L1 has been reported in a few series . Chowdhury et al documented a correlation between PD‐L1 expression of tumor cells and a poor prognosis in patients with thyroid cancer, a greater risk of recurrence, and a shortened disease‐free survival .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

PD‐L1 and thyroid cytology: A possible diagnostic and prognostic marker

Dell’Aquila

Granitto

Martini

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

Background Programmed death‐ligand 1 (PD‐L1) expression is emerging as an important predictive biomarker in anti–PD‐L1 cancer immunotherapy. Its role has been clearly defined in various human cancers and is linked to a poor prognosis and resistance to anticancer therapies. The role of PD‐L1 in thyroid cancers has not been well defined in fine‐needle aspiration cytology (FNAC). The authors examined the performance of PD‐L1 immunostaining in liquid‐based cytology (LBC) to determine whether it could be a biomarker of malignancy or aggressive disease. Methods From January 2018 to March 2019, 236 thyroid lesions, which had been diagnosed by FNAC as indeterminate lesions, suspicious for malignancy (SFM), and malignant, were enrolled. PD‐L1 immunostaining was performed on both LBC and corresponding histology samples. Results The FNAC cohort included 50 benign negative controls, 42 samples of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), 33 samples of follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), 53 samples that were suspicious for malignancy (SFM), and 58 malignant samples. AUS/FLUS samples included 3 goiters, 32 follicular adenomas (FAs), 1 noninvasive follicular thyroid neoplasm with papillary‐like nuclear features (NIFTP), 5 invasive follicular variants of papillary thyroid carcinoma (I‐FVPTCs), and 1 follicular carcinoma; whereas FN/SFN samples included 24 FAs and 9 malignancies (4 I‐FVPTCs, 1 NIFTP, 3 papillary thyroid carcinomas [PTCs], and 1 oncocytic follicular carcinoma). The 53 SFM samples were diagnosed on histopathology as 2 FAs, 5 NIFTPs, 15 I‐FVPTCs, and 31 PTCs; whereas the 58 malignant specimens included 5 NIFTPs, 5 I‐FVPTCs, and 48 PTCs. Increased plasma membrane and cytoplasmic PD‐L1 expression was found in 79 cases (38.5%), including 61 PTCs (conventional and variants). Negative PD‐L1 expression was found in NIFTPs and FAs. A BRAF V600E mutation was identified in 15% of PD‐L1–positive malignancies. Conclusions The current data suggest that PD‐L1 expression in the thyroid gland might represent a marker of malignancy that correlates with PTC, but not with NIFTP. Thyroid neoplasms with PD‐L1 expression also ae enriched with BRAF V600E mutations, suggesting that they are associated with more aggressive behavior.

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 81%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

PD‐L1 and thyroid cytology: A possible diagnostic and prognostic marker

Dell’Aquila

Granitto

Martini

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

show abstract

Analysis of anti‐apoptotic PVT1 oncogene and apoptosis‐related proteins (p53, Bcl2, PD‐1, and PD‐L1) expression in thyroid carcinoma

Ibrahiem

Makhdoom

Alanazi

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis

et al. 2018

View full text Add to dashboard Cite

There is evidence that programmed death-ligand 1 (PD-L1) is expressed by thyroid follicular epithelium in thyroiditis, but the role of PD-L1 in papillary thyroid carcinoma (PTC) is poorly understood. We aimed to determine whether (1) the presence of background chronic lymphocytic thyroiditis (CLT) or Hashimoto thyroiditis (HT) influenced the expression of PD-L1 in benign follicular epithelium or in PTC and (2) if PD-L1 expression in PTC persisted with lymph node metastasis. We performed immunohistochemistry (IHC) for PD-L1 on formalin-fixed paraffin-embedded tissues. We first studied five cases of unremarkable thyroid, five cases of CLT, and five cases of HT without carcinoma. We subsequently performed PD-L1 IHC on ten cases of PTC arising in normal thyroid, ten cases of PTC arising in CLT, and ten cases of PTC arising in HT. Whenever available, we evaluated corresponding synchronous lymph node metastases from all cases for PD-L1 expression. PD-L1 expression was increased (10-90%) in all five cases of HT, only minimal expressed (1-5%) in two of five cases of CLT, and not expressed in five cases of unremarkable thyroid. PTC arising in normal thyroid or CLT nearly uniformly lacked PD-L1 expression. In contrast, PTC arising in HT demonstrated significant PD-L1 expression, which persisted in corresponding lymph node metastases. Background non-neoplastic follicular epithelium in the HT cases also demonstrated PD-L1 expression. Thyroid follicular epithelium in HT demonstrates increased PD-L1 expression, and PTC arising in a background of HT shows increased PD-L1 expression, which is retained with metastasis.

show abstract

Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma

Cited by 17 publications

References 29 publications

PD‐L1 and thyroid cytology: A possible diagnostic and prognostic marker

PD‐L1 and thyroid cytology: A possible diagnostic and prognostic marker

Analysis of anti‐apoptotic PVT1 oncogene and apoptosis‐related proteins (p53, Bcl2, PD‐1, and PD‐L1) expression in thyroid carcinoma

Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis

Contact Info

Product

Resources

About